Quarterly ResultMay 13, 2026, 04:13 PM
Journey Medical Q1 Revenue +21% to $16.0M; Adj. EBITDA $0.6M
AI Summary
Journey Medical Corporation reported strong financial results for the first quarter ended March 31, 2026, with total revenues increasing 21% year-over-year to $16.0 million. The company narrowed its net loss to $2.2 million and achieved positive Adjusted EBITDA of $0.6 million, driven by robust performance of Emrosi® which generated $6.3 million in revenue. Journey Medical also strengthened its cash position to $27.2 million and expanded market access for Emrosi® through a new Group Purchasing Organization contract covering 85% of commercial lives.
Key Highlights
- Total revenues increased 21% year-over-year to $16.0 million for Q1 2026.
- Emrosi® revenues were $6.3 million in Q1 2026, up from $2.1 million in Q1 2025.
- Net loss narrowed to $2.2 million, or $(0.08) per share, in Q1 2026.
- Adjusted EBITDA was positive $0.6 million, or $0.02 per share, in Q1 2026.
- Cash and cash equivalents increased to $27.2 million at March 31, 2026.
- Emrosi® prescriptions totaled 29,968 for Q1 2026, up from 27,023 in Q4 2025.
- Secured a GPO contract for Emrosi® providing access to approximately 85% of all commercial lives.
- Gross margin decreased to 61.0% in Q1 2026 from 63.5% due to a $1.3 million non-recurring charge.